Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    thumbnail
    Making sense of the rapidly changing biosimilars landscape

    Strategies for adapting and achieving optimal market access

    thumbnail
    Building a comparative evidence base using network meta-analysis

    Methods, implementation and reporting

    FSA_thumbnail
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    Watch the webinar.

    thumbnail
    ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Social media image
ICON Plc logo
ICON Plc

Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...

24 Mar
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

2026 will be a pivotal year for Europe’s HTA landscape. The Work Program forecasts: - \~50 JCAs for medicinal products - The first assessments of high risk medical devices - A fully operational HTA IT platform - More pre...

24 Mar
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

2026 will be a pivotal year for Europe’s HTA landscape. The Work Program forecasts: - ~50 JCAs for medicinal products - The first assessments of high risk medical devices - A fully operational HTA IT platform - More pred...

24 Mar
1
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

24 Mar
1
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

24 Mar
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

ICON will be attending the 20th #WRIB from 13–17 April at the Hyatt Regency Dallas. Meet ICON’s experts at booth \#31 to discuss how our PK, immunogenicity, biomarker, qPCR and flow cytometry expertise across small mole...

23 Mar
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON will be attending the 20th #WRIB from 13–17 April at the Hyatt Regency Dallas. Meet ICON’s experts at booth #31 to discuss how our PK, immunogenicity, biomarker, qPCR and flow cytometry expertise across small molec...

23 Mar
1
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Attending World Vaccine Congress? Join ICON’s Dinah Knotts-Keeterle on 1 April at 12:10 pm as she discusses on ‘AI and the future of vaccine studies from reaction to readiness’. Learn more. https://ow.ly/GzT350Yr8Y8

23 Mar
3
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Join Thanh-Long Nguyen and other industry experts to discuss the latest developments in flow cytometry. This panel hosted by Bioanalysis Zone will explore how innovation is reshaping assay development and clinical trial ...

23 Mar
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

As the CRA role evolves, so do the opportunities for career progression. From In-House CRA to Clinical Trial Manager, Huseyin's journey highlights how roles are expanding and creating new opportunities for growth. Regi...

23 Mar
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Patient led organisations are actively shaping scientific and regulatory pathways in ultra rare diseases. Our recent webinar captured powerful examples of how real people are accelerating progress to meet needs, deliver ...

23 Mar
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Thank you to everyone who joined our Rare Disease Day webinar. The inspiring discussion highlighted the results of patients’ and parents’ relentless advocacy, including scientific breakthroughs and regulatory progress in...

23 Mar
1
View post
View webpage
  • Previous
  • 1
  • …
  • 4
  • 5
  • 6
  • …
  • 94
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence